Peter Cameron

Peter Cameron has extensive work experience in the field of gene editing and technology development. Peter is currently the VP of gene editing at Profluent Bio, a position they have held since 2023. Prior to this, they worked as the Executive Director of Technology at Spotlight Therapeutics from 2021 to 2023. In this role, they were responsible for the strategic vision and advancement of technology for the company's platform, with a focus on CRISPR effectors for in vivo delivery. Before joining Spotlight Therapeutics, Peter worked at Caribou Biosciences, where they held the roles of Associate Director of Technology Development from 2020 to 2021, and Senior Research Scientist from 2014 to 2020. Peter'scontributions at Caribou Biosciences included leading efforts in gene editing platforms, CRISPR effector engineering, and developing novel genome editing platforms. Prior to their industry roles, Peter was a Postdoctoral fellow at The Scripps Research Institute from 2011 to 2014, and a Graduate Student at UC Berkeley from 2004 to 2010, where they conducted research on taste transduction and discovered novel sensory components.

Peter Cameron received their Doctor of Philosophy (Ph.D.) in Molecular Biology from the University of California, Berkeley from 2004 to 2010. Prior to that, they obtained their Bachelor of Science (BS) degree in Zoology from the University of Wisconsin-Madison between 1998 and 2002.